|Videos|July 22, 2020

A World Without Antibiotics? Why Patients Should Care About Resistance

Dr. Pol Vandenbroucke describes the individual and collective risks associated with rising antibiotic resistance.

Even before the COVID-19 pandemic, it was difficult to articulate the great importance of careful prescribing to patients who request antibiotic treatment. Common misnomers like "strong antibiotic" point to widespread confusion on how antibiotics function.

Dr. Pol Vandenbroucke, Chief Medical Officer for Pfizer’s hospital business unit, describes the individual and collective risks associated with antimicrobial resistance from a patient perspective.

Dr. Vandenbroucke then proceeds to compare the ramifications with the impact of COVID-19 on travel and other social activity.


Related to this article

This Week's Top 5 Infectious Disease News Stories: September 12-September 18, 2026
In this week's top infectious disease stories, a Pennsylvania teen became the state's fourth measles death in weeks, the CDC reported a 17% summer surge in rabies exposure calls, new research revisited whether cefepime raises mortality risk, a multihospital review examined ceftriaxone's safety after state alerts, and examining Legionella pneumonia diagnostics.
Ceftriaxone Safety: Separating Signal From Risk
A retrospective multihospital study found that severe adverse events occurred at similarly low rates with ceftriaxone and other IV cephalosporins suggesting there is no evidence to support avoiding ceftriaxone despite recent health department safety alerts.
Treatment of Latent Tuberculosis in a Trice
A retrospective study of 225 patients across Cook County Department of Health clinics found that the novel 1-month 1HP regimen (isoniazid plus rifapentine) for latent TB infection had a completion rate comparable to standard longer regimens and was well tolerated, suggesting it may be a viable shorter alternative.
Peggy Lillis Foundation Will Honor C diff Advocates at Annual Gala
The Peggy Lillis Foundation will host its 17th Annual Changing the Odds Gala this month in New York City, and it will include a casino, fellowship amongst the C diff community, and an award ceremony honoring a physician-scientist, philanthropist, a researcher, and a patient advocate for their contributions to C difficile awareness, treatment, and prevention.